# Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

> **NCT04780035** · PHASE3 · COMPLETED · sponsor: **Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"** · enrollment: 3000 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
- **OTHER:** Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)

## Key facts

- **NCT ID:** NCT04780035
- **Lead sponsor:** Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-27
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-12-20
- **Target enrollment:** 3000 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04780035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04780035, "Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04780035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*